U-IMGN

Q:IMGN - IMMUNOGEN INC - http://www.immunogen.com

21:15:54 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
IMGN - Q	0.1	14.11	·	17.80	0.1	15.87	-0.13	-0.8	3,640.0	55,985	17,892	16.03 16.11 15.755	20.69 3.605	19:51:19	17:00	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Down -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - Last 10 of 17892

More trades...

Time ET	Ex	Price	Change	Volume
19:51:19	Q	15.60	-0.40	1
18:28:00	Q	15.87	-0.13	5
18:22:52	Q	15.50	-0.50	15
18:20:00	Q	15.86	-0.14	45
18:09:47	Q	15.60	-0.40	1
18:06:52	Q	15.87	-0.13	108
18:05:38	Q	15.87	-0.13	8
17:14:03	Q	15.87	-0.13	73,575
17:13:14	Q	15.86	-0.14	15
16:53:55	Q	15.87	-0.13	20

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2023-09-29 17:00	U:IMGN	News Release200	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-28 07:00	U:IMGN	News Release200	ELAHERE ‚ ® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FR Ž ±-Positive Platinum-Resistant Ovarian Cancer
2023-09-18 17:00	U:IMGN	News Release200	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-18 06:30	U:IMGN	News Release200	ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
2023-09-05 16:30	U:IMGN	News Release200	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Date ET

Symbol

Type

Headline

2023-09-29 17:00

U:IMGN

News Release

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2023-09-28 07:00

U:IMGN

News Release

ELAHERE ‚ ® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FR Ž ±-Positive Platinum-Resistant Ovarian Cancer